57 results
Page 2 of 3
PRER14A
gxzbgw 2ed
10 Apr 20
Preliminary revised proxy
4:38pm
PREM14A
164d52sua8tkk8
6 Mar 20
Preliminary proxy related to merger
5:32pm
8-K
EX-2.1
fygcv7qv
18 Dec 19
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement
8:13am
DEFA14A
EX-2.1
6zxi49jl
18 Dec 19
Additional proxy soliciting materials
8:11am
8-K
EX-99.1
ivtagxha5m y6jk
11 Mar 19
Results of Operations and Financial Condition
4:12pm
8-K
EX-1.1
w8qi56 sy4
9 Nov 18
Entry into a Material Definitive Agreement
5:10pm
424B5
lp3avogz6a
9 Nov 18
Prospectus supplement for primary offering
4:49pm
8-K
EX-1.1
tg6oig 5qgrcsm
28 Jun 18
Zafgen Announces Proposed Offering of Common Stock
5:01pm
424B5
odzgjc0gofgku 2fji
28 Jun 18
Prospectus supplement for primary offering
4:54pm
424B5
van27xv oo0hqh2
27 Jun 18
Prospectus supplement for primary offering
4:49pm
8-K
EX-99.1
67v9s4cuh qhfn2
7 Jun 18
Zafgen, Inc. Appoints Industry Veteran and Healthcare Policy Expert Dr. Wendy Everett to its Board of Directors
5:06pm
8-K
EX-99.1
53v2th 2p
12 Oct 17
Zafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific Officer
12:00am